Literature DB >> 12706864

Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities.

Young-Ju Jang1, Kill Soon Park, Hee-Yong Chung, Hyung-Il Kim.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to exert potent cytotoxic activity against many tumor cells but not normal cells. However, some tumor cells are resistant to TRAIL, and it has not been determined how this occurs. In the present study, we obtained three subgroups of Jurkat clones with TRAIL-sensitive, -partial resistant and -resistant phenotypes. We found that most TRAIL-resistant and -partial resistant clones expressed low levels of DR5, whereas most TRAIL-sensitive clones expressed high levels of Death Receptor (DR5). However, there were clones with a range of different TRAIL-sensitivities that had similar levels of DR5 expression. The expression levels of DR4 and the decoy receptors, DcR1 and DcR2, did not correlate with TRAIL sensitivities. We also compared the subgroups in terms of the expression of Fas-associated death domain protein (FADD), the levels of activation of Receptor Interacting Protein (RIP) and caspases, and cleavage of Poly (ADP-Ribose)Polymerase (PARP). Basal expression levels of FADD were not significantly different among the subgroups. After treatment with TRAIL, both TRAIL-sensitive and partial resistant clones showed high levels of activation of caspase-3, caspase-8, RIP and PARP. Relative basal level and induced level of Phosphoprotein over Expressed in Diabetes/Phosphoprotein Enriched in Astrocytes (PED/PEA-15) after TRAIL treatment were compared in the clones. Basal levels of PED/PEA-15 expression were similar among sensitive, partial resistant and resistant clones. TRAIL did not change the PED/PEA-15 level in the clones. In addition, transduction and expression of the dominant negative form of the I-kBalpha gene did not change TRAIL-sensitivities. Our results showed that the expression levels of DR5, the activation levels of caspase-8, -3 and RIP were critical factors in determining TRAIL-sensitivities in Jurkat cells. The results of our study also suggest that cells with different TRAIL-sensitivities arise through multiple mechanisms even within a single cell line.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706864     DOI: 10.1016/s0304-3835(02)00680-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  TLR4 activates NF-κB in human ovarian granulosa tumor cells.

Authors:  Dori C Woods; Yvonne A R White; Caroline Dau; A L Johnson
Journal:  Biochem Biophys Res Commun       Date:  2011-05-17       Impact factor: 3.575

2.  Caspase selective reagents for diagnosing apoptotic mechanisms.

Authors:  Marcin Poreba; Katarzyna Groborz; Mario Navarro; Scott J Snipas; Marcin Drag; Guy S Salvesen
Journal:  Cell Death Differ       Date:  2018-05-10       Impact factor: 15.828

Review 3.  Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Authors:  Hope M Amm; Patsy G Oliver; Choo Hyung Lee; Yufeng Li; Donald J Buchsbaum
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

4.  Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

Authors:  Xiaobing Tian; Jiangbin Ye; Michelle Alonso-Basanta; Stephen M Hahn; Constantinos Koumenis; Jay F Dorsey
Journal:  J Biol Chem       Date:  2011-06-22       Impact factor: 5.157

5.  Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5.

Authors:  Young-Hwa Jung; Jeonghoon Heo; Yong J Lee; Taeg Kyu Kwon; Young-Ho Kim
Journal:  Life Sci       Date:  2010-01-21       Impact factor: 5.037

6.  Phenethyl isothiocyanate enhances TRAIL-induced apoptosis in oral cancer cells and xenografts.

Authors:  Cheng-Chang Yeh; Hui-Hsin Ko; Yu-Ping Hsieh; King-Jean Wu; Mark Yen-Ping Kuo; Yi-Ting Deng
Journal:  Clin Oral Investig       Date:  2016-01-29       Impact factor: 3.573

7.  Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480.

Authors:  Li-Hong Xu; Chang-Sheng Deng; You-Qing Zhu; Shi-Quan Liu; Dong-Zhou Liu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

8.  Modeling the effects of a Staphylococcal Enterotoxin B (SEB) on the apoptosis pathway.

Authors:  Brandon W Higgs; John Dileo; Wenling E Chang; Haley B Smith; Olivia J Peters; Rasha Hammamieh; Marti Jett; Jordan C Feidler
Journal:  BMC Microbiol       Date:  2006-05-31       Impact factor: 3.605

9.  HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.

Authors:  L Pukac; P Kanakaraj; R Humphreys; R Alderson; M Bloom; C Sung; T Riccobene; R Johnson; M Fiscella; A Mahoney; J Carrell; E Boyd; X T Yao; L Zhang; L Zhong; A von Kerczek; L Shepard; T Vaughan; B Edwards; C Dobson; T Salcedo; V Albert
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

10.  Ursodeoxycholic Acid Induces Death Receptor-mediated Apoptosis in Prostate Cancer Cells.

Authors:  Won Sup Lee; Ji Hyun Jung; Radha Panchanathan; Jeong Won Yun; Dong Hoon Kim; Hye Jung Kim; Gon Sup Kim; Chung Ho Ryu; Sung Chul Shin; Soon Chan Hong; Yung Hyun Choi; Jin-Myung Jung
Journal:  J Cancer Prev       Date:  2017-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.